These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 27919526

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia.
    Janjetovic S, Rolling CC, Budde U, Schneppenhem S, Schafhausen P, Peters MC, Bokemeyer C, Holstein K, Langer F.
    Thromb Res; 2022 Oct; 218():35-43. PubMed ID: 35988442
    [Abstract] [Full Text] [Related]

  • 4. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts.
    Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y, Nakamura H, Nakayama T, Komatsu N.
    Eur J Haematol; 2022 Dec; 109(6):779-786. PubMed ID: 36130908
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [Abstract] [Full Text] [Related]

  • 8. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.
    Rottenstreich A, Kleinstern G, Amsalem H, Kalish Y.
    J Thromb Thrombolysis; 2018 Oct 20; 46(3):304-309. PubMed ID: 29654448
    [Abstract] [Full Text] [Related]

  • 12. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr 20; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients.
    Mital A, Prejzner W, Bieniaszewska M, Hellmann A.
    Pol Arch Med Wewn; 2015 Apr 20; 125(12):914-20. PubMed ID: 26658493
    [Abstract] [Full Text] [Related]

  • 14. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 20; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 15. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera - retrospective analysis of 142 consecutive cases.
    Mital A, Prejzner W, Świątkowska-Stodulska R, Hellmann A.
    Thromb Res; 2015 Oct 20; 136(4):754-7. PubMed ID: 26269222
    [Abstract] [Full Text] [Related]

  • 16. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 20; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 17. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Jun 20; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
    Abdulkarim K, Samuelsson J, Johansson P, Andréasson B.
    Eur J Haematol; 2017 Jun 20; 98(6):577-583. PubMed ID: 28251679
    [Abstract] [Full Text] [Related]

  • 19. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP, Tian HY, Tan M, Wu Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun 20; 26(3):842-848. PubMed ID: 29950230
    [Abstract] [Full Text] [Related]

  • 20. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm.
    Song IC, Kang S, Lee MW, Ryu H, Lee HJ, Yun HJ, Jo DY.
    Blood Res; 2023 Mar 31; 58(1):42-50. PubMed ID: 36774948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.